These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23883936)

  • 1. Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.
    Rhinn H; Fujita R; Qiang L; Cheng R; Lee JH; Abeliovich A
    Nature; 2013 Aug; 500(7460):45-50. PubMed ID: 23883936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of Late Onset Alzheimer's Disease and Anticipation Effect of Genome-Wide Significant Risk Variants: Pilot Study of the APOE e4 Allele.
    De Luca V; Spalletta G; Souza RP; Graff A; Bastos-Rodrigues L; Camargos Bicalho MA
    Neuropsychobiology; 2019; 77(1):8-12. PubMed ID: 30110694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Genomic Analysis Revealed Associated Genes for Alzheimer's Disease in APOE4 Non-Carriers.
    Jiang S; Zhang CY; Tang L; Zhao LX; Chen HZ; Qiu Y
    Curr Alzheimer Res; 2019; 16(8):753-763. PubMed ID: 31441725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astrocytes down-regulate neuronal beta-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner.
    Vincent B; Smith JD
    Eur J Neurosci; 2001 Jul; 14(2):256-66. PubMed ID: 11553277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CD33 rs3865444:C˃A polymorphism with a reduced risk of late-onset Alzheimer's disease in Slovaks is limited to subjects carrying the APOE ε4 allele.
    Javor J; Ďurmanová V; Párnická Z; Minárik G; Králová M; Pečeňák J; Vašečková B; Režnáková V; Šutovský S; Gmitterová K; Hromádka T; Peterajová Ľ; Shawkatová I
    Int J Immunogenet; 2020 Oct; 47(5):397-405. PubMed ID: 32333488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN pathway in Alzheimer's disease pathogenesis.
    Bracher-Smith M; Leonenko G; Baker E; Crawford K; Graham AC; Salih DA; Howell BW; Hardy J; Escott-Price V
    Neurobiol Aging; 2022 Nov; 119():67-76. PubMed ID: 35977442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.
    Sando SB; Melquist S; Cannon A; Hutton ML; Sletvold O; Saltvedt I; White LR; Lydersen S; Aasly JO
    BMC Neurol; 2008 Apr; 8():9. PubMed ID: 18416843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.
    Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R
    J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of the short variant of the 5-HTTPLR polymorphism and the apoE epsilon4 allele does not increase the risk for late onset Alzheimer's disease.
    Oliveira JR; Shimokomaki CM; Brito-Marques PR; Gallindo RM; Okuma M; Maia LG; Otto PA; Passos-Bueno MR; Zatz M
    Mol Psychiatry; 1999 Jan; 4(1):19-20. PubMed ID: 10089003
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
    Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.
    Bussy A; Snider BJ; Coble D; Xiong C; Fagan AM; Cruchaga C; Benzinger TLS; Gordon BA; Hassenstab J; Bateman RJ; Morris JC;
    Neurobiol Aging; 2019 Mar; 75():42-50. PubMed ID: 30530186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of β-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ε4 Status: Impact for Risk and Progression of Alzheimer Disease.
    Nyarko JNK; Quartey MO; Pennington PR; Heistad RM; Dea D; Poirier J; Baker GB; Mousseau DD
    Neuroscience; 2018 Mar; 373():20-36. PubMed ID: 29331531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease.
    Pievani M; Galluzzi S; Thompson PM; Rasser PE; Bonetti M; Frisoni GB
    Neuroimage; 2011 Apr; 55(3):909-19. PubMed ID: 21224004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater effect of polygenic risk score for Alzheimer's disease among younger cases who are apolipoprotein E-ε4 carriers.
    Fulton-Howard B; Goate AM; Adelson RP; Koppel J; Gordon ML; ; Barzilai N; Atzmon G; Davies P; Freudenberg-Hua Y
    Neurobiol Aging; 2021 Mar; 99():101.e1-101.e9. PubMed ID: 33164815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease.
    Pardo JV; Lee JT;
    eNeuro; 2018; 5(1):. PubMed ID: 29497704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
    Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
    Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling APOE ɛ3/4 allele-associated sporadic Alzheimer's disease in an induced neuron.
    Kim H; Yoo J; Shin J; Chang Y; Jung J; Jo DG; Kim J; Jang W; Lengner CJ; Kim BS; Kim J
    Brain; 2017 Aug; 140(8):2193-2209. PubMed ID: 28899010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers.
    Yoshiiwa A; Kamino K; Yamamoto H; Kobayashi T; Imagawa M; Nonomura Y; Yoneda H; Sakai T; Nishiwaki Y; Sato N; Rakugi H; Miki T; Ogihara T
    Ann Neurol; 1997 Jul; 42(1):115-7. PubMed ID: 9225693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study.
    Lambert JC; Sleegers K; González-Pérez A; Ingelsson M; Beecham GW; Hiltunen M; Combarros O; Bullido MJ; Brouwers N; Bettens K; Berr C; Pasquier F; Richard F; Dekosky ST; Hannequin D; Haines JL; Tognoni G; Fiévet N; Dartigues JF; Tzourio C; Engelborghs S; Arosio B; Coto E; De Deyn P; Del Zompo M; Mateo I; Boada M; Antunez C; Lopez-Arrieta J; Epelbaum J; Schjeide BM; Frank-Garcia A; Giedraitis V; Helisalmi S; Porcellini E; Pilotto A; Forti P; Ferri R; Delepine M; Zelenika D; Lathrop M; Scarpini E; Siciliano G; Solfrizzi V; Sorbi S; Spalletta G; Ravaglia G; Valdivieso F; Vepsäläinen S; Alvarez V; Bosco P; Mancuso M; Panza F; Nacmias B; Bossù P; Hanon O; Piccardi P; Annoni G; Mann D; Marambaud P; Seripa D; Galimberti D; Tanzi RE; Bertram L; Lendon C; Lannfelt L; Licastro F; Campion D; Pericak-Vance MA; Soininen H; Van Broeckhoven C; Alpérovitch A; Ruiz A; Kamboh MI; Amouyel P
    J Alzheimers Dis; 2010; 22(1):247-55. PubMed ID: 20847397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.